@article{article, title = {{The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial}}, publisher = {{Springer Nature}}, url = {{http://eprints.whiterose.ac.uk/142352/ }}, year = {{2018}}, month = {{12}}, author = {{Striha A and Ashcroft AJ and Hockaday A and Cairns DA and Boardman K and Jacques G and Williams C and Snowden JA and Garg M and Cavenagh J and Yong K et al}}, doi = {{10.1186/s13063-018-2524-8}}, volume = {{19}}, journal = {{Trials}}, issue = {{1}}, note = {{Accessed on 2025/04/10}}}